Patents by Inventor Laurence J. Blumberg

Laurence J. Blumberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF ANTI-FCRN ANTIBODIES IN THE TREATMENT OF PEMPHIGHUS AND PEMPHIGOID DISEASES
    Publication number: 20220298241
    Abstract: The disclosure relates to methods for treating pemphigus and/or a pemphigoid disease in a subject in need thereof, wherein the methods include administering to a subject in need thereof a therapeutically effective amount of an FcRn inhibitor. In certain embodiments, the FcRn inhibitor is an anti-FcRn antibody or antigen-binding fragment thereof.
    Type: Application
    Filed: May 18, 2020
    Publication date: September 22, 2022
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventors: Laurence J. Blumberg, Richard S. Blumberg, John Humphries
  • Humanized affinity matured anti-FcRn antibodies
    Patent number: 10822417
    Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to human serum albumin. The FcRn-binding proteins can be used to treat a variety of disorders including acute and chronic toxic exposure.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: November 3, 2020
    Assignee: Syntimmune, Inc.
    Inventors: Laurence J. Blumberg, Richard S. Blumberg, Susan D. Jones, Derry Roopenian, Robert George E. Holgate, Timothy D. Jones, Arron R. Hearn
  • HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIES
    Publication number: 20200207854
    Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to IgG Fc. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: February 25, 2020
    Publication date: July 2, 2020
    Inventors: Laurence J. Blumberg, Richard S. Blumberg, Susan D. Jones, Derry Roopenian, Robert George Edward Holgate, Timothy David Jones, Arron Robert Hearn
  • HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIES
    Publication number: 20200181262
    Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to IgG Fc. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: February 25, 2020
    Publication date: June 11, 2020
    Inventors: Laurence J. Blumberg, Richard S. Blumberg, Susan D. Jones, Derry Roopenian, Robert George Edward Holgate, Timothy David Jones, Arron Robert Hearn
  • Humanized affinity matured anti-FcRn antibodies
    Patent number: 10626175
    Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to IgG Fc. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: April 21, 2020
    Assignee: SYNTIMMUNE, INC.
    Inventors: Laurence J. Blumberg, Richard S. Blumberg, Susan Dana Jones, Derry Roopenian, Robert George Edward Holgate, Timothy David Jones, Arron Robert Hearn
  • HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIES
    Publication number: 20190135915
    Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to human serum albumin. The FcRn-binding proteins can be used to treat a variety of disorders including acute and chronic toxic exposure.
    Type: Application
    Filed: April 25, 2017
    Publication date: May 9, 2019
    Inventors: Laurence J. Blumberg, Richard S. Blumberg, Susan D. Jones, Derry Roopenian, Robert George E. Holgate, Timothy D. Jones, Arron R. Hearn
  • HUMAZNIZED AFFINITY MATURED ANIT-FcRn ANTIBODIES
    Publication number: 20180291101
    Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to IgG Fc. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: November 13, 2017
    Publication date: October 11, 2018
    Inventors: Laurence J. Blumberg, Richard S. Blumberg, Susan Dana Jones, Derry Roopenian, Robert George Edward Holgate, Timothy David Jones, Arron Robert Hearn